Real-world evidence from USER confirms that ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg provides predictable intraocular pressure (IOP) response when used per label USER data showed no significant difference in rates of IOP-related events before and after ILUVIEN treatment1 Patients who had an IOP response of ≤ 25 mm Hg associated with a prior steroid treatment were 94% to 98% likely to have an IOP response ≤ 25 mm Hg associated with ILUVIEN A 94% predictive value is calculated using the maximum IOP measured on ILUVIEN and a 98% predictive value is calculated using the last measured IOP value on ILUVIENa aNegative predictive value could not be adequately determined because so few patients were treated with ILUVIEN where the IOP on the prior steroid was > 25 mm Hg. USER data: IOP-related events before and after ILUVIEN, entire population (N = 160 eyes)1 USER data showed no significant increase in the number of patients treated with IOP-lowering medication after ILUVIEN treatment USER data: IOP-lowering medication on day of and after ILUVIEN, entire population (N = 160 eyes)1 P=0.169 vs baseline.FAMESafety DataThe real-world safety of ILUVIEN mirrors outcomes seen in the Phase 3 clinical trials. SEE THE DATAPATIENTcase studySee how Dr. Kitchens managed a patient with clinically non-significant IOP elevations. REVIEW CASE STUDY